Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 38366255)

  • 1. Tumor acidosis-induced DNA damage response and tetraploidy enhance sensitivity to ATM and ATR inhibitors.
    Aubert L; Bastien E; Renoult O; Guilbaud C; Özkan K; Brusa D; Bouzin C; Richiardone E; Richard C; Boidot R; Léonard D; Corbet C; Feron O
    EMBO Rep; 2024 Mar; 25(3):1469-1489. PubMed ID: 38366255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.
    Turchick A; Zimmermann A; Chiu LY; Dahmen H; Elenbaas B; Zenke FT; Blaukat A; Vassilev LT
    Mol Cancer Ther; 2023 Jul; 22(7):859-872. PubMed ID: 37079339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress.
    Lloyd RL; Urban V; Muñoz-Martínez F; Ayestaran I; Thomas JC; de Renty C; O'Connor MJ; Forment JV; Galanty Y; Jackson SP
    Nucleic Acids Res; 2021 Sep; 49(15):8665-8683. PubMed ID: 34329458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATM and ATR as therapeutic targets in cancer.
    Weber AM; Ryan AJ
    Pharmacol Ther; 2015 May; 149():124-38. PubMed ID: 25512053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
    Teng PN; Bateman NW; Darcy KM; Hamilton CA; Maxwell GL; Bakkenist CJ; Conrads TP
    Gynecol Oncol; 2015 Mar; 136(3):554-61. PubMed ID: 25560806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
    Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
    Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.
    Menezes DL; Holt J; Tang Y; Feng J; Barsanti P; Pan Y; Ghoddusi M; Zhang W; Thomas G; Holash J; Lees E; Taricani L
    Mol Cancer Res; 2015 Jan; 13(1):120-9. PubMed ID: 25232030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of ataxia telangiectasia mutated kinase inhibitors.
    Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
    Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer.
    Durinikova E; Reilly NM; Buzo K; Mariella E; Chilà R; Lorenzato A; Dias JML; Grasso G; Pisati F; Lamba S; Corti G; Degasperi A; Cancelliere C; Mauri G; Andrei P; Linnebacher M; Marsoni S; Siena S; Sartore-Bianchi A; Nik-Zainal S; Di Nicolantonio F; Bardelli A; Arena S
    Clin Cancer Res; 2022 Sep; 28(17):3874-3889. PubMed ID: 35881546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Adenovirus E4orf4 Protein Provides a Novel Mechanism for Inhibition of the DNA Damage Response.
    Brestovitsky A; Nebenzahl-Sharon K; Kechker P; Sharf R; Kleinberger T
    PLoS Pathog; 2016 Feb; 12(2):e1005420. PubMed ID: 26867009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
    Gulliver C; Hoffmann R; Baillie GS
    Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
    Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
    Cui Y; Palii SS; Innes CL; Paules RS
    Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
    Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
    Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Versatility of the Mec1
    Corcoles-Saez I; Dong K; Cha RS
    Curr Genet; 2019 Jun; 65(3):657-661. PubMed ID: 30610294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
    Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
    Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
    Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATM and ATR Expression Potentiates HBV Replication and Contributes to Reactivation of HBV Infection upon DNA Damage.
    Kostyusheva A; Brezgin S; Bayurova E; Gordeychuk I; Isaguliants M; Goptar I; Urusov F; Nikiforova A; Volchkova E; Kostyushev D; Chulanov V
    Viruses; 2019 Oct; 11(11):. PubMed ID: 31683589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways.
    Ito SS; Nakagawa Y; Matsubayashi M; Sakaguchi YM; Kobashigawa S; Matsui TK; Nanaura H; Nakanishi M; Kitayoshi F; Kikuchi S; Kajihara A; Tamaki S; Sugie K; Kashino G; Takahashi A; Hasegawa M; Mori E; Kirita T
    J Biol Chem; 2020 Sep; 295(37):12946-12961. PubMed ID: 32675286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.